0
Obstructive Lung Diseases |

A Comparison of Study Designs of Inhaled Agents in Non-Cystic Fibrosis Bronchiectasis (NCFB): Key Differences in the Phase 3 RESPIRE Trials of Ciprofloxacin Dry Powder for Inhalation (DPI)

Timothy Aksamit, MD; Anthony De Soyza, MD; Elisabeth Operschall, MD; Tiemo-Joerg Bandel, MD; Robert Wilson, MD
Author and Funding Information

Mayo Clinic, Rochester, MN


Chest. 2015;148(4_MeetingAbstracts):662A. doi:10.1378/chest.2277297
Text Size: A A A
Published online

Abstract

SESSION TITLE: Asthma - Bronchiectasis Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: Ciprofloxacin DPI is in development to reduce the frequency of acute exacerbations in patients with NCFB. We compared the study design of the two Ciprofloxacin DPI Phase 3 RESPIRE trials with other Phase 3 study designs from recent or ongoing NCFB trials of inhaled agents.

METHODS: Study designs for the Phase 3 RESPIRE trials were obtained from Bayer internal protocols. Comparative Phase 3 study design elements for aztreonam for inhalation (Barker et al., Lancet Respir Med 2014), dual-release ciprofloxacin for inhalation (Clinicaltrials.gov and clinicaltrialsregister.eu), colistin (Haworth et al. AJRCC 2014), and mannitol (Bilton et al. Chest 2013; Bilton et al. Thorax 2014) were extracted from the published literature or online sources.

RESULTS: NCFB trials of inhaled agents evaluate the common objective of reducing exacerbations, but study designs show substantial variations. In addition to differences in the agents and formulations/mode of delivery, there are key differences in study design elements among these trials, including entry criteria, pre-defined pathogens, and requirements for protocol-defined exacerbations. The RESPIRE entry criteria require a patient history of ≥2 prior exacerbations/yr and specific baseline pathogens (Pseudomonas aeruginosa or 6 other Gram-positive or Gram-negative respiratory pathogens). Protocol-defined exacerbations in RESPIRE require both initiation of systemic antibiotic therapy and a symptom duration of at least 2 days. Treatment regimens vary widely among NCFB studies, and treatment durations range from 12 to 52 weeks. RESPIRE is the first Phase 3 NCFB development program to test two different treatment cycles: 14 days on/14 days off therapy and 28 days on/28 days off over 48 weeks of treatment. Further, subjects in RESPIRE will be stratified by positive P. aeruginosa culture and chronic macrolide use.

CONCLUSIONS: Key study design elements differ among Phase 3 clinical trials of inhaled agents in patients with NCFB. The RESPIRE trials features unique elements that will advance our understanding of NCFB treatment, including a rigorous definition of exacerbation, both 14- and 28-day treatment cycles, inclusion of patients with P. aeruginosa or other relevant pathogens, and stratification for chronic macrolide therapy.

CLINICAL IMPLICATIONS: Comparing study design elements will lead to a better understanding of optimal NCFB trial design and improve identification of patients most likely to benefit from inhaled therapies.

DISCLOSURE: Anthony De Soyza: Consultant fee, speaker bureau, advisory committee, etc.: Fees from Almirall, AstraZeneca, Bayer, Chiesi, Forest Laboratories, GSK, and Novartis, Grant monies (from industry related sources): AstraZeneca, Gilead, Bayer, Forest Laboratories, and Novartis Elisabeth Operschall: Employee: Nothing else to disclose Tiemo-Joerg Bandel: Employee: Nothing else to disclose Robert Wilson: Consultant fee, speaker bureau, advisory committee, etc.: Bayer for lectures and advisory board memberships The following authors have nothing to disclose: Timothy Aksamit

Presentation will involve study designs of inhaled agents for non-cystic fibrosis bronchiectasis. Some of studies have already been published, some are unpublished and ongoing.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543